References
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-532.
Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inwardNa1 current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262:99-108.
Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 1995;91:1799-1806.
Yue L, Feng J, Li GR, Nattel S. Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol (Lond) 1996;496:647-662.
Li GR, Feng J, Wang Z, Fermini B, Nattel S. Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. Circ Res 1996;78:903-915.
Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993;72:75-83.
Sager PT. The frequency-dependent effects of dofetilide in humans. Circulation 1995;92:1I-744. (Abstract).
Bargheer K, Bode F, Klein HU, Trappe HJ, Franz MR, Lichtlen PR. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J 1994;15:1409-1414.
Yuan S, Wohlfart B, Rasmussen HS, Olsson S, Blomstrom-Lundqvist C. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. A study using simultaneous monophasic action potential recordings from two sites in the right ventricle. Eur Heart J 1994;15:514-522.
Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992;70:1432-1437.
Nademanee K, Bailey W, O'Neill G, Satler C, Freidrich T. Electrophysiologic and hemodynamic effects of dofetilide in patients with left ventricular function: a randomized, double-blind, placebo-controlled study. PACE 1998;In press: (Abstract)
DeCara J, Pollak A, Dubrey S, Briggs L, Falk R. Positive atrial inotropic effects of dofetilide following cardioversion of atrial fibrillation. J Am Coll Cardiol 1998;432A-433A.
Singh S, Berk M, Yellen L, et al. Efficacy and safety of oral dofetilide in maintaining normal sinus in patients with atrial fibrillation/flutter: A multicenter study. Circulation 1998;96(8):I383:2145-2145.(Abstract).
Singh S, Berk M, Zoble R, Abrahamson D, Satler C, Freidrich T. Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: A multicenter study. J Am Coll Cardiol 1998;31: 369A-370A.(Abstract).
Singh S, Berk M, Yellen L, Abrahamson D. Restoration and maintenance of sinus rhythm reduces frequency and severity of symptoms associated with atrial fibrillation and flutter. PACE 1998;In press: (Abstract)
Bashir Y, Thomsen PE, Kingma JH, Moller M, Wong C, Cobbe SM, Jordaens L, Campbell RW, Rasmussen HS, Camm AI. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Am J Cardiol 1995;76:1040-1044.
Ferguson J. Clinical trials. Clin Cardiol 1998;21:51-54.
Waldo AL, Camm AJ, de RH, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol. Lancet 1996;348:7-12.
Fermini B, Jurkiewicz NK, Jow B, Guinosso PJJ, Baskin EP, Lynch JJJ, Salata JJ. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995;26:259-271.
Salata J, Brooks R. Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovasc Drug Rev 1997;15(2):137-156.
Nair LA, Grant AO. Emerging class III antiarrhythmic agents: Mechanism of action and proarrhythmic potential. Cardiovasc Drugs Ther 1997;11:149-167.
Liu L, Nattel S. Relative effects of an IKr selective blocker (Dofetilide) and a drug with significant IKs blocking action (Azimilide) in experimental atrial fibrillation. Can J Cardiol 1996;12(Suppl E). (Abstract).
Drexler AP, Micklas JM, Brooks RR. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. J Cardiovasc Pharmacol 1996;28:848-855.
Friedrichs GS, Abreu JN, Driscoll EMJ, Borlak J, Lucchesi BR. Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation. J Cardiovasc Pharmacol 1998;31:56-66.
Chi L, Park JL, Friedrichs GS, Banglawala YA, Perez MA, Tanhehco EJ, Lucchesi BR. Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br J Pharmacol 1996;117:1261-1269.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sager, P.T. Investigational Antiarrhythmic Agents. Card Electrophysiol Rev 2, 232–235 (1998). https://doi.org/10.1023/A:1009956806133
Issue Date:
DOI: https://doi.org/10.1023/A:1009956806133